Neoplastic Syndromes, Hereditary
The condition of a pattern of malignancies within a family, but not every individual's necessarily having the same neoplasm. Characteristically the tumor tends to occur at an earlier than average age, individuals may have more than one primary tumor, the tumors may be multicentric, usually more than 25 percent of the individuals in direct lineal descent from the proband are affected, and the cancer predisposition in these families behaves as an autosomal dominant trait with about 60 percent penetrance.
Subtype terms (14)
More specific conditions that are subtypes of Neoplastic Syndromes, Hereditary in the MeSH hierarchy.
- Adenomatous Polyposis Coli
40 drugs (19 approved, 21 experimental)
- Basal Cell Nevus Syndrome
17 drugs (13 approved, 4 experimental)
- Birt-Hogg-Dube Syndrome
2 drugs approved
- Colorectal Neoplasms, Hereditary Nonpolyposis
24 drugs (19 approved, 5 experimental)
- Dysplastic Nevus Syndrome
1 drug experimental
- Exostoses, Multiple Hereditary
1 drug approved
- Hamartoma Syndrome, Multiple
6 drugs (4 approved, 2 experimental)
- Hereditary Breast and Ovarian Cancer Syndrome
10 drugs (6 approved, 4 experimental)
- Li-Fraumeni Syndrome
2 drugs approved
- Multiple Endocrine Neoplasia
6 drugs (5 approved, 1 experimental)
- Neurofibromatoses
21 drugs (17 approved, 4 experimental)
- Peutz-Jeghers Syndrome
4 drugs approved
- Tuberous Sclerosis
16 drugs (11 approved, 5 experimental)
- Wilms Tumor
83 drugs (51 approved, 32 experimental)
Drugs by status
Phase 3 trials (4)
Phase 2 trials (8)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 2 Indications (1)